Sphingolipids and lysosomal pathologies.

[1]  K. Sandhoff,et al.  The role of sphingolipid metabolism in cutaneous permeability barrier formation. , 2014, Biochimica et Biophysica Acta.

[2]  Emil Alexov,et al.  A mutation in a ganglioside biosynthetic enzyme, ST3GAL5, results in salt & pepper syndrome, a neurocutaneous disorder with altered glycolipid and glycoprotein glycosylation. , 2014, Human molecular genetics.

[3]  M. Patterson.  Gangliosidoses. , 2013, Handbook of clinical neurology.

[4]  Jennifer C. Lee,et al.  Saposin C protects glucocerebrosidase against α-synuclein inhibition. , 2013, Biochemistry.

[5]  G. Nürnberg,et al.  Impaired epidermal ceramide synthesis causes autosomal recessive congenital ichthyosis and reveals the importance of ceramide acyl chain length. , 2013, The Journal of investigative dermatology.

[6]  Roger L. Williams,et al.  Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi , 2013, Nature.

[7]  A. Ferbert,et al.  Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. , 2013, American journal of human genetics.

[8]  P. Saftig,et al.  Lysosomal Membrane Proteins and Their Central Role in Physiology , 2013, Traffic.

[9]  K. Sandhoff,et al.  Gangliosides and Gangliosidoses: Principles of Molecular and Metabolic Pathogenesis , 2013, The Journal of Neuroscience.

[10]  J. Degen,et al.  Inactivation of Ceramide Synthase 6 in Mice Results in an Altered Sphingolipid Metabolism and Behavioral Abnormalities* , 2013, The Journal of Biological Chemistry.

[11]  M. Nalls,et al.  A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. , 2013, JAMA neurology.

[12]  R. Heilig,et al.  Mutations in CERS3 Cause Autosomal Recessive Congenital Ichthyosis in Humans , 2013, PLoS genetics.

[13]  E. Schuchman,et al.  Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer , 2013, PloS one.

[14]  M. Beer,et al.  Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications , 2013, Journal of internal medicine.

[15]  K. Sandhoff.  My journey into the world of sphingolipids and sphingolipidoses , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[16]  P. Saftig,et al.  Sensitivity to Lysosome-Dependent Cell Death Is Directly Regulated by Lysosomal Cholesterol Content , 2012, PloS one.

[17]  J. Degen,et al.  Ablation of Neuronal Ceramide Synthase 1 in Mice Decreases Ganglioside Levels and Expression of Myelin-associated Glycoprotein in Oligodendrocytes* , 2012, The Journal of Biological Chemistry.

[18]  A. Rötig,et al.  Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency , 2012, European Journal of Human Genetics.

[19]  R. Desnick,et al.  Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. , 2012, Annual review of genomics and human genetics.

[20]  M. Overholtzer,et al.  Autophagy proteins in macroendocytic engulfment. , 2012, Trends in cell biology.

[21]  K. Willecke,et al.  Loss of ceramide synthase 3 causes lethal skin barrier disruption. , 2012, Human molecular genetics.

[22]  S. Ishii,et al.  Pharmacological chaperone therapy for Fabry disease , 2012, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[23]  M. V. van Breemen,et al.  Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. , 2011, Blood.

[24]  J. Kornhuber,et al.  Activity of secretory sphingomyelinase is increased in plasma of alcohol-dependent patients. , 2011, Alcoholism, clinical and experimental research.

[25]  K. Sandhoff,et al.  Biological Function of the Cellular Lipid BMP—BMP as a Key Activator for Cholesterol Sorting and Membrane Digestion , 2011, Neurochemical Research.

[26]  Andrea Ballabio,et al.  TFEB Links Autophagy to Lysosomal Biogenesis , 2011, Science.

[27]  K. Sandhoff,et al.  Lysosomal lipid storage diseases. , 2011, Cold Spring Harbor perspectives in biology.

[28]  J. Vance,et al.  Function of the Niemann–Pick type C proteins and their bypass by cyclodextrin , 2011, Current opinion in lipidology.

[29]  Yusuf A. Hannun,et al.  A Deficiency of Ceramide Biosynthesis Causes Cerebellar Purkinje Cell Neurodegeneration and Lipofuscin Accumulation , 2011, PLoS genetics.

[30]  K. Sandhoff,et al.  Regulation of the NPC2 protein‐mediated cholesterol trafficking by membrane lipids , 2011, Journal of neurochemistry.

[31]  G. Schwarzmann,et al.  Role of endosomal membrane lipids and NPC2 in cholesterol transfer and membrane fusion[S] , 2010, Journal of Lipid Research.

[32]  Y. Hannun,et al.  The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. , 2010, Current molecular medicine.

[33]  L. Masuelli,et al.  Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting. , 2010, Human molecular genetics.

[34]  R. Sandhoff.  Very long chain sphingolipids: Tissue expression, function and synthesis , 2010, FEBS letters.

[35]  A. Futerman,et al.  Mammalian ceramide synthases , 2010, IUBMB life.

[36]  H. Gröne,et al.  Hepatic glycosphingolipid deficiency and liver function in mice , 2010, Hepatology.

[37]  F. Platt,et al.  Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases* , 2010, The Journal of Biological Chemistry.

[38]  E. Schuchman,et al.  Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  C. Gong,et al.  Deregulation of sphingolipid metabolism in Alzheimer's disease , 2010, Neurobiology of Aging.

[40]  J. Hurley,et al.  Molecular Mechanism of Multivesicular Body Biogenesis by ESCRT Complexes , 2010, Nature.

[41]  S. Ben-Dor,et al.  A Critical Role for Ceramide Synthase 2 in Liver Homeostasis , 2010, The Journal of Biological Chemistry.

[42]  Liana C. Silva,et al.  A Critical Role for Ceramide Synthase 2 in Liver Homeostasis , 2010, The Journal of Biological Chemistry.

[43]  T. Hornemann,et al.  Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids*♦ , 2010, The Journal of Biological Chemistry.

[44]  A. Zylicz,et al.  Hsp70 stabilizes lysosomes and reverts Niemann–Pick disease-associated lysosomal pathology , 2010, Nature.

[45]  J. Opferman,et al.  GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. , 2009, Molecular cell.

[46]  J. Degen,et al.  Adult Ceramide Synthase 2 (CERS2)-deficient Mice Exhibit Myelin Sheath Defects, Cerebellar Degeneration, and Hepatocarcinomas* , 2009, The Journal of Biological Chemistry.

[47]  E. Snyder,et al.  Neural Stem Cell Transplantation Benefits a Monogenic Neurometabolic Disorder During the Symptomatic Phase of Disease , 2009, Stem cells.

[48]  J. Storch,et al.  Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking. , 2009, Biochimica et biophysica acta.

[49]  A. Brech,et al.  Multivesicular Endosome Biogenesis in the Absence of ESCRTs , 2009, Traffic.

[50]  Joseph L. Goldstein,et al.  Structure of N-Terminal Domain of NPC1 Reveals Distinct Subdomains for Binding and Transfer of Cholesterol , 2009, Cell.

[51]  H. McMahon,et al.  Mechanisms of endocytosis. , 2009, Annual review of biochemistry.

[52]  J. Gratton,et al.  Sphingosine-1-Phosphate: A Novel Nonhypoxic Activator of Hypoxia-Inducible Factor-1 in Vascular Cells , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[53]  J. Storch,et al.  Regulation of sterol transport between membranes and NPC2. , 2008, Biochemistry.

[54]  J. Goldstein,et al.  NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes , 2008, Proceedings of the National Academy of Sciences.

[55]  Xianlin Han,et al.  Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice , 2008, Human molecular genetics.

[56]  C. Ficicioglu.  Review of miglustat for clinical management in Gaucher disease type 1 , 2008, Therapeutics and clinical risk management.

[57]  F. Platt,et al.  Substrate reduction therapy , 2008, Acta paediatrica.

[58]  G. van Meer,et al.  No ESCRTs for Exosomes , 2008, Science.

[59]  R. Brady,et al.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.

[60]  P. Saftig,et al.  LIMP-2 Is a Receptor for Lysosomal Mannose-6-Phosphate-Independent Targeting of β-Glucocerebrosidase , 2007, Cell.

[61]  G. van Meer,et al.  Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis , 2007, The Journal of cell biology.

[62]  S. van Weely,et al.  Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. , 2007, Blood.

[63]  E. Schuchman,et al.  The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann–Pick disease , 2007, Journal of Inherited Metabolic Disease.

[64]  K. Sandhoff,et al.  Saposin B mobilizes lipids from cholesterol‐poor and bis(monoacylglycero)phosphate‐rich membranes at acidic pH , 2007, The FEBS journal.

[65]  Martin Hermansson,et al.  Both Sphingomyelin Synthases SMS1 and SMS2 Are Required for Sphingomyelin Homeostasis and Growth in Human HeLa Cells* , 2007, Journal of Biological Chemistry.

[66]  Jae-Ho Park,et al.  Acid ceramidase is a novel factor required for early embryo survival , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  H. Gröne,et al.  Integrity and Barrier Function of the Epidermis Critically Depend on Glucosylceramide Synthesis* , 2007, Journal of Biological Chemistry.

[68]  K. Sandhoff,et al.  Sphingolipid metabolism diseases. , 2006, Biochimica et biophysica acta.

[69]  L. Naldini,et al.  Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. , 2006, The Journal of clinical investigation.

[70]  Ralf Klingenstein,et al.  Saposin A Mobilizes Lipids from Low Cholesterol and High Bis(monoacylglycerol)phosphate-containing Membranes , 2006, Journal of Biological Chemistry.

[71]  S. Karlsson,et al.  Effective cell and gene therapy in a murine model of Gaucher disease , 2006, Proceedings of the National Academy of Sciences.

[72]  Y. Jigami,et al.  Molecular pathologies of and enzyme replacement therapies for lysosomal diseases. , 2006, CNS & neurological disorders drug targets.

[73]  Seng H. Cheng,et al.  Effective gene therapy in an authentic model of Tay-Sachs-related diseases , 2006, Proceedings of the National Academy of Sciences.

[74]  S. Withers,et al.  Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis. , 2006, Journal of molecular biology.

[75]  R. Proia,et al.  Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.

[76]  P. Bauer,et al.  Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study , 2005, The Lancet.

[77]  J. Kornhuber,et al.  High activity of acid sphingomyelinase in major depression , 2005, Journal of Neural Transmission.

[78]  M. Hojjati,et al.  Serine palmitoyl-CoA transferase (SPT) deficiency and sphingolipid levels in mice. , 2005, Biochimica et biophysica acta.

[79]  W. Sly,et al.  Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[80]  K. Sandhoff,et al.  Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. , 2005, Annual review of cell and developmental biology.

[81]  A. Martin-Villalba,et al.  [Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth]. , 2005, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[82]  F. Sharom,et al.  The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. , 2005, The Biochemical journal.

[83]  C. Wessig,et al.  Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. , 2005, Human molecular genetics.

[84]  B. Cormand,et al.  A mutation within the saposin D domain in a Gaucher disease patient with normal glucocerebrosidase activity , 2005, Human Genetics.

[85]  R. Proia,et al.  Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[86]  H. Mandel,et al.  A mutation in the saposin A coding region of the prosaposin gene in an infant presenting as Krabbe disease: first report of saposin A deficiency in humans. , 2005, Molecular genetics and metabolism.

[87]  R. Proia,et al.  Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720* , 2004, Journal of Biological Chemistry.

[88]  F. Gage,et al.  Intracerebral Transplantation of Adult Mouse Neural Progenitor Cells into the Niemann-Pick-A Mouse Leads to a Marked Decrease in Lysosomal Storage Pathology , 2004, The Journal of Neuroscience.

[89]  R. Dwek,et al.  Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase , 2004, Nature Genetics.

[90]  W. Krivit.  Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases , 2004, Springer Seminars in Immunopathology.

[91]  A. Futerman,et al.  The pathogenesis of glycosphingolipid storage disorders. , 2004, Seminars in cell & developmental biology.

[92]  S. Withers,et al.  Pharmacological Enhancement of β-Hexosaminidase Activity in Fibroblasts from Adult Tay-Sachs and Sandhoff Patients* , 2004, Journal of Biological Chemistry.

[93]  C. Ackerley,et al.  Role of Multiple Drug Resistance Protein 1 in Neutral but Not Acidic Glycosphingolipid Biosynthesis* , 2004, Journal of Biological Chemistry.

[94]  K. Sandhoff,et al.  Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine , 2004, FEBS letters.

[95]  K. Dobrenis.  Cell-mediated delivery systems , 2004 .

[96]  M. Wendeler,et al.  Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation. , 2004, European journal of biochemistry.

[97]  Satoshi Yasuda,et al.  Molecular machinery for non-vesicular trafficking of ceramide , 2003, Nature.

[98]  Seiichiro Ogawa,et al.  Chemical chaperone therapy for brain pathology in GM1-gangliosidosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  R. D'Hooge,et al.  Metachromatic leukodystrophy: consequences of sulphatide accumulation , 2003, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[100]  E. Schuchman,et al.  The Reverse Activity of Human Acid Ceramidase* , 2003, Journal of Biological Chemistry.

[101]  R. Proia.  Glycosphingolipid functions: insights from engineered mouse models. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[102]  C. Hollak,et al.  Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[103]  Timm Maier,et al.  The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease. , 2003, Journal of molecular biology.

[104]  R. Proia,et al.  Enhanced insulin sensitivity in mice lacking ganglioside GM3 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  P. Saftig,et al.  At the acidic edge: emerging functions for lysosomal membrane proteins. , 2003, Trends in cell biology.

[106]  L. Riboni,et al.  Salvage pathways in glycosphingolipid metabolism. , 2003, Biochimie.

[107]  T. Linke,et al.  Human acid sphingomyelinase - Assignment of the disulfide bond pattern , 2003 .

[108]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[109]  Kazuro Furukawa,et al.  Refractory Skin Injury in Complex Knock-out Mice Expressing Only the GM3 Ganglioside* , 2002, The Journal of Biological Chemistry.

[110]  Alfred H. Merrill,et al.  De Novo Sphingolipid Biosynthesis: A Necessary, but Dangerous, Pathway* , 2002, The Journal of Biological Chemistry.

[111]  R. Proia,et al.  Combinatorial Ganglioside Biosynthesis* , 2002, The Journal of Biological Chemistry.

[112]  S. Milstien,et al.  Sphingosine 1-Phosphate, a Key Cell Signaling Molecule* , 2002, The Journal of Biological Chemistry.

[113]  K. Fukushima,et al.  Paranodal junction formation and spermatogenesis require sulfoglycolipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[114]  J. Aerts,et al.  Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. , 2002, Blood cells, molecules & diseases.

[115]  R. Proia,et al.  Physiological Substrates for Human Lysosomal β-Hexosaminidase S* , 2002, The Journal of Biological Chemistry.

[116]  Kazuro Furukawa,et al.  b-series Ganglioside Deficiency Exhibits No Definite Changes in the Neurogenesis and the Sensitivity to Fas-mediated Apoptosis but Impairs Regeneration of the Lesioned Hypoglossal Nerve* , 2002, The Journal of Biological Chemistry.

[117]  K. Sandhoff,et al.  Sphingolipid Activator Proteins , 2002 .

[118]  A. Blume,et al.  Interaction of the GM2-activator protein with phospholipid-ganglioside bilayer membranes and with monolayers at the air-water interface. , 2001, European journal of biochemistry.

[119]  K. Sandhoff,et al.  Sphingolipid activator proteins: proteins with complex functions in lipid degradation and skin biogenesis. , 2001, Glycobiology.

[120]  K. Sandhoff,et al.  Degradation of membrane-bound ganglioside GM2 by beta -hexosaminidase A. Stimulation by GM2 activator protein and lysosomal lipids. , 2001, The Journal of biological chemistry.

[121]  J. Crawley,et al.  Mice Expressing Only Monosialoganglioside GM3 Exhibit Lethal Audiogenic Seizures* , 2001, The Journal of Biological Chemistry.

[122]  S. Brahmbhatt,et al.  Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I , 2001, Nature Genetics.

[123]  T. Linke,et al.  Interfacial Regulation of Acid Ceramidase Activity , 2001, The Journal of Biological Chemistry.

[124]  T. Linke,et al.  Stimulation of Acid Sphingomyelinase Activity by Lysosomal Lipids and Sphingolipid Activator Proteins , 2001, Biological chemistry.

[125]  C. Scriver.  The Metabolic and Molecular Bases of Inherited Disease , 2001 .

[126]  R. Wattiaux,et al.  Identification of HE1 as the second gene of Niemann-Pick C disease. , 2000, Science.

[127]  T. Linke,et al.  Degradation of Membrane-bound Ganglioside GM1 , 2000, The Journal of Biological Chemistry.

[128]  W. Krivit,et al.  Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. , 1999, Current opinion in hematology.

[129]  C. Deng,et al.  [A vital role for glycosphingolipid synthesis during development and differentiation]. , 1999, Seikagaku. The Journal of Japanese Biochemical Society.

[130]  W. Möbius,et al.  Intracellular Distribution of a Biotin-labeled Ganglioside, GM1, by Immunoelectron Microscopy After Endocytosis in Fibroblasts , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[131]  P. Elias,et al.  Sphingolipid Activator Proteins Are Required for Epidermal Permeability Barrier Formation* , 1999, The Journal of Biological Chemistry.

[132]  W. Krivit,et al.  Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. , 1999, Current opinion in neurology.

[133]  R. Proia,et al.  Accumulation of protein‐bound epidermal glucosylceramides in β‐glucocerebrosidase deficient type 2 Gaucher mice , 1999, FEBS letters.

[134]  T. Linke,et al.  Lysosomal Degradation on Vesicular Membrane Surfaces , 1998, The Journal of Biological Chemistry.

[135]  T. Daly,et al.  Gene therapy for lysosomal storage diseases. , 1998, Expert opinion on investigational drugs.

[136]  R. Clément,et al.  Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways. , 1998, Glycobiology.

[137]  P. Steinert,et al.  Ceramides Are Bound to Structural Proteins of the Human Foreskin Epidermal Cornified Cell Envelope* , 1998, The Journal of Biological Chemistry.

[138]  R. Proia,et al.  Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[139]  Kunihiko Suzuki.  Twenty Five Years of the “Psychosine Hypothesis”: A Personal Perspective of its History and Present Status , 1998, Neurochemical Research.

[140]  T. Levade,et al.  Saposins (sap) A and C activate the degradation of galactosylceramide in living cells , 1997, FEBS letters.

[141]  K. G. Coleman,et al.  Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. , 1997, Science.

[142]  R. Proia,et al.  Mice deficient in all forms of lysosomal beta-hexosaminidase show mucopolysaccharidosis-like pathology. , 1997, Journal of neuropathology and experimental neurology.

[143]  W. Möbius,et al.  Accumulation of sphingolipids in SAP-precursor (prosaposin)-deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. , 1997, European journal of cell biology.

[144]  B. Martin,et al.  Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. , 1997, Archives of biochemistry and biophysics.

[145]  K. Sandhoff,et al.  Biosynthesis, Processing, and Targeting of Sphingolipid Activator Protein (SAP)Precursor in Cultured Human Fibroblasts , 1996, The Journal of Biological Chemistry.

[146]  K. Takamiya,et al.  Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[147]  A. Bosio,et al.  Molecular cloning and characterization of the mouse CGT gene encoding UDP-galactose ceramide-galactosyltransferase (cerebroside synthetase). , 1996, Genomics.

[148]  U. Francke,et al.  Molecular cloning, chromosomal mapping, and characterization of the mouse UDP-galactose:ceramide galactosyltransferase gene. , 1996, Genomics.

[149]  R. Salvayre,et al.  Accurate Differentiation of Neuronopathic and Nonneuronopathic Forms of Niemann‐Pick Disease by Evaluation of the Effective Residual Lysosomal Sphingomyelinase Activity in Intact Cells , 1994, Journal of neurochemistry.

[150]  K. Sandhoff,et al.  The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. , 1994, Biological chemistry Hoppe-Seyler.

[151]  K. Sandhoff,et al.  Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. , 1994, Biochemical and biophysical research communications.

[152]  E. Ginns,et al.  Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease. , 1994, The Journal of clinical investigation.

[153]  F. Wieland,et al.  Lactosylceramide is synthesized in the lumen of the Golgi apparatus , 1994, FEBS letters.

[154]  K. Sandhoff,et al.  Ganglioside metabolism. Enzymology, Topology, and regulation. , 1993, The Journal of biological chemistry.

[155]  K. Sandhoff,et al.  Activator proteins and topology of lysosomal sphingolipid catabolism. , 1992, Biochimica et biophysica acta.

[156]  S. Michel,et al.  Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease , 1992, Human Genetics.

[157]  J. Dambrosia,et al.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.

[158]  K. Kretz,et al.  Characterization of a mutation in a family with saposin B deficiency: a glycosylation site defect. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[159]  R. Brady,et al.  Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[160]  Farrow Br.  Replacement therapy for inherited enzyme deficiencies. , 1989 .

[161]  B. Fenderson,et al.  Specific interaction between Lex and Lex determinants. A possible basis for cell recognition in preimplantation embryos and in embryonal carcinoma cells. , 1989, The Journal of biological chemistry.

[162]  E. Hay,et al.  Cell Biology of Extracellular Matrix , 1988, Springer US.

[163]  S. Sonnino,et al.  Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. , 1988, Journal of Biological Chemistry.

[164]  K. Sandhoff,et al.  Acid sphingomyelinase from human urine: purification and characterization. , 1987, Biochimica et biophysica acta.

[165]  K. Sandhoff,et al.  Specificity of human glucosylceramide β‐glucosidase towards synthetic glucosylsphingolipids inserted into liposomes , 1986 .

[166]  K. Sandhoff,et al.  Evidence for two different active sites on human beta-hexosaminidase A. Interaction of GM2 activator protein with beta-hexosaminidase A. , 1985, The Journal of biological chemistry.

[167]  R. Rousson,et al.  Biochemical studies in Niemann‐Pick disease. III: In vitro and in vivo assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease , 1985, Clinical genetics.

[168]  D. Solter,et al.  Stage‐specific embryonic antigens (SSEA‐3 and ‐4) are epitopes of a unique globo‐series ganglioside isolated from human teratocarcinoma cells. , 1983, The EMBO journal.

[169]  K. Sandhoff,et al.  Activator protein for the degradation of globotriaosylceramide by human alpha-galactosidase. , 1983, The Journal of biological chemistry.

[170]  K. Sandhoff,et al.  Variant of GM2‐gangliosidosis with hexosaminidase A having a severely changed substrate specificity. , 1983, The EMBO journal.

[171]  M. Vanier.  Biochemical studies in Niemann-Pick disease. I. Major sphingolipids of liver and spleen. , 1983, Biochimica et biophysica acta.

[172]  J. Månsson,et al.  The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease. , 1982, Biochimica et biophysica acta.

[173]  L. Svennerholm,et al.  Accumulation of Glucosylceramide and Glucosylsphingosine (Psychosine) in Cerebrum and Cerebellum in Infantile and Juvenile Gaucher Disease , 1982, Journal of neurochemistry.

[174]  K. Sandhoff,et al.  Cerebroside sulfatase activator deficiency induced metachromatic leukodystrophy. , 1981, American journal of human genetics.

[175]  K. Sandhoff,et al.  AB variant of infantile GM2 gangliosidosis: deficiency of a factor necessary for stimulation of hexosaminidase A-catalyzed degradation of ganglioside GM2 and glycolipid GA2. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[176]  W. Mraz,et al.  Low molecular weight proteins in secondary lysosomes as activators of different sphingolipid hydrolases , 1976, FEBS letters.

[177]  R. Giugliani,et al.  The mucopolysaccharidoses. , 1976, Journal of medical genetics.

[178]  R. Brady,et al.  Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. , 1974, The New England journal of medicine.

[179]  R. Brady,et al.  Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. , 1973, The New England journal of medicine.

[180]  K. Suzuki,et al.  Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase. , 1970, Proceedings of the National Academy of Sciences of the United States of America.

[181]  J. O'brien,et al.  Generalized Gangliosidosis: Beta-Galactosidase Deficiency , 1968, Science.

[182]  K. Sandhoff,et al.  Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs. , 1968, Pathologia Europaea.

[183]  A. D. Patrick.  A Deficiency of Glucocerebrosidase in Gaucher's Disease , 1965 .

[184]  R. Brady,et al.  METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE. , 1965, Biochemical and biophysical research communications.

[185]  Jennifer C. Lee,et al.  Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. , 2013, Molecular genetics and metabolism.

[186]  T. Hla.  Sphingosine 1-phosphate , 2012 .

[187]  R. Yu,et al.  Structures, biosynthesis, and functions of gangliosides--an overview. , 2011, Journal of oleo science.

[188]  Jian‐Qiang Fan,et al.  A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity , 2008, Biological chemistry.

[189]  E. Gulbins,et al.  Physiological and pathophysiological aspects of ceramide. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[190]  IN PREPARATION , 2006 .

[191]  K. Sandhoff,et al.  Diagnosis of infantile and juvenile forms of GM2 gangliosidosis variant 0. residual activities toward natural and different synthetic substrates , 2004, Human Genetics.

[192]  T. Sugiura,et al.  Imbalanced substrate specificity of mutant beta-galactosidase in patients with Morquio B disease. , 2003, Molecular genetics and metabolism.

[193]  R. Proia,et al.  Physiological substrates for human lysosomal beta -hexosaminidase S. , 2002, The Journal of biological chemistry.

[194]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .

[195]  A. Pshezhetsky,et al.  Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology. , 2001, Progress in nucleic acid research and molecular biology.

[196]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[197]  F. Sanmartí,et al.  Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant , 1999, Acta Neuropathologica.

[198]  K. Higaki,et al.  [Niemann-Pick disease [type A and B] (acid sphingomyelinase deficiencies)]. , 1998, Ryoikibetsu shokogun shirizu.

[199]  E. Ginns,et al.  Epidermal Abnormalities May Distinguish Type 2 from Type 1 and Type 3 of Gaucher Disease , 1996, Pediatric Research.

[200]  K. Suzuki,et al.  Sphingolipid activator proteins. , 1995, Essays in biochemistry.

[201]  R. Linke,et al.  Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. , 1986, Biological chemistry Hoppe-Seyler.

[202]  H. Egge,et al.  Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. , 1986, Biological chemistry Hoppe-Seyler.

[203]  K. Sandhoff,et al.  Specificity of human glucosylceramide beta-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system. , 1986, European journal of biochemistry.

[204]  Elizabeth Sattely.  Biosynthesis , 1981, Antibiotics.

[205]  J. Månsson,et al.  Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. , 1980, Journal of lipid research.

[206]  H. Jatzkewitz,et al.  Eine Cerebrosidsulfatase aus Schweineniere , 1964 .

[207]  K. Sandhoff,et al.  On a biochemically special form of infantile amaturotic idiocy. , 1963, Biochimica et biophysica acta.